不同脱细胞真皮基质在乳房再造中的比较:50/50研究
该回顾性队列比较DermACELL与AlloDerm Ready To Use在乳房再造中的结局,各50只乳房。DermACELL组红乳综合征发生率显著更低(0%对26%,p=0.0001),引流管拔除时间更短(15.8天对20.6天,p=0.017),其他并发症无显著差异。
要点
- DermACELL组红乳综合征发生率为0%,AlloDerm组为26%,差异显著。
- DermACELL组引流管拔除时间平均15.8天,短于AlloDerm组的20.6天。
- 血清肿、感染、皮瓣坏死及假体取出等并发症两组无显著差异。
核心结论
- 与AlloDerm Ready To Use相比,使用DermACELL行乳房再造的患者引流管拔除天数更少、红乳综合征发生率更低,其他并发症发生率相当。
研究设计与样本
- 回顾性病历审查,纳入58例连续患者共100只乳房,DermACELL组30例50只乳房,AlloDerm Ready To Use组28例50只乳房。
- 乳房切除由三位不同的乳腺外科医生完成,所有再造由同一位整形外科医生完成。
- 统计分析采用Fisher精确检验。
主要发现
- 两组平均年龄、体重指数、接受新辅助/辅助化疗或乳腺放疗的比例、治疗性及预防性乳房切除数量差异均无统计学意义(p<0.05)。
- DermACELL组红乳综合征发生率为0%,AlloDerm组为26%,差异显著(p=0.0001)。
- DermACELL组引流管拔除时间平均15.8天,AlloDerm组为20.6天,差异显著(p=0.017)。
- 血清肿、血肿、延迟愈合、感染、皮瓣坏死或假体取出方面未见显著差异。
临床怎么用
- 在即刻乳房再造选择脱细胞真皮基质时,可考虑DermACELL以降低红乳综合征风险并缩短引流管留置时间。
- 需向患者说明两种基质在血清肿、感染、皮瓣坏死及假体取出等主要并发症方面发生率相当。
局限性
- 为回顾性单中心研究,样本量有限(58例患者100只乳房)。
- 证据等级为治疗性III级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acellular dermal matrix has enjoyed extensive use in primary and secondary alloplastic breast aesthetic and reconstructive surgery. The objective of this study was to examine clinical outcomes between available acellular dermal matrix products: DermACELL (LifeNet Health, Virginia Beach, Va.) and AlloDerm Ready To Use (LifeCell Corp., Branchburg, N.J.). METHODS: A retrospective chart review was performed on 58 consecutive patients (100 breasts) reconstructed with either DermACELL (n = 30 patients; 50 breasts) or AlloDerm Ready To Use (n = 28 patients; 50 breasts). The mastectomies were performed by three different breast surgeons. All reconstructions were performed by the same plastic surgeon (T.A.P.). Statistical analysis was performed by means of Fisher's exact test. RESULTS: Differences in the average age, body mass index, percentage having neoadjuvant/adjuvant chemotherapy or breast irradiation, and numbers of therapeutic and prophylactic mastectomies between the two groups were not statistically significant (p < 0.05). Complications in both cohorts of patients were clinically recorded for 90 days after immediate reconstruction. When comparing outcomes, patients in the DermACELL group had a significantly lower incidence of "red breast syndrome" (0 percent versus 26 percent; p = 0.0001) and fewer days before drain removal (15.8 days versus 20.6 days; p = 0.017). No significant differences were seen in terms of seroma, hematoma, delayed healing, infection, flap necrosis, or explantation. CONCLUSION: Patients reconstructed with DermACELL as compared with AlloDerm Ready To Use have significantly decreased number of days to drain removal and red breast syndrome and equivalent rates of other complications, including seroma, infection, flap necrosis, and explantation. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
引用
- Pittman TA, Fan KL, Knapp A, et al. Comparison of Different Acellular Dermal Matrices in Breast Reconstruction: The 50/50 Study. Plast Reconstr Surg. 2017. PMID: 28234811. doi:10.1097/PRS.0000000000003048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。